Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 30, Status: Authorised
Agenda - HMA/EMA Annual Data Forum 2025
Quality of medicines questions and answers: Part 1
Human medicines European public assessment report (EPAR): Dectova, zanamivir, Date of authorisation: 26/04/2019, Revision: 8, Status: Authorised
Annex to agenda of the CHMP meeting 10-13 November 2025
Agenda of the CHMP meeting 10-13 November 2025
Human medicines European public assessment report (EPAR): Oyavas, bevacizumab, Date of authorisation: 26/03/2021, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Rezdiffra, resmetirom, Date of authorisation: 18/08/2025, Status: Authorised
Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2025
Human medicines European public assessment report (EPAR): HBVaxPro, hepatitis B vaccine (recombinant DNA), Date of authorisation: 27/04/2001, Revision: 35, Status: Authorised